Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.2010721296855
   PubMed Web of Science ®Google Scholar
• Komposch K, Sibilia M. EGFR signaling in liver diseases. Int J Mol Sci. 2015;17(1):pii: E30. doi:10.3390/ijms17010030
   PubMed Web of Science ®Google Scholar
• Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3(4):353–367. doi:10.1586/egh.09.3519673623
   PubMedGoogle Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-719095497
   PubMed Web of Science ®Google Scholar
• Ikeda S, Tsigelny IF, Skjevik ÅA, et al. Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. Oncologist. 2018;23(5):586–593. doi:10.1634/theoncologist.2017-047929487225
   PubMed Web of Science ®Google Scholar
• Nikolova D, Chalovska V, Ivanova M, et al. Immunohistochemical expression of epidermal growth factor receptor in hepatocellular carcinoma. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2018;39(2–3):21–28. doi:10.2478/prilozi-2018-003830864368
   PubMedGoogle Scholar
• Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6(1):32–43. doi:10.1038/nrm154815688065
   PubMed Web of Science ®Google Scholar
• Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol. 2006;291(1):C1–10. doi:10.1152/ajpcell.00620.200516769815
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–1174. doi:10.1056/NEJMra070770418337605
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol. 2006;290(2):L209–21. doi:10.1152/ajplung.00185.200516403941
   PubMed Web of Science ®Google Scholar
• Peschos D, Damala C, Stefanou D, et al. Expression of matrix metalloproteinase‑9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol. 2006;21(6):603‑8.
   PubMed Web of Science ®Google Scholar
• Chang SH, Kanasaki K, Gocheva V, et al. VEGF-A induces angiogenesis by perturbing the cathepsin‑cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009;69(10):4537–4544. doi:10.1158/0008-5472.CAN-08-453919435903
   PubMed Web of Science ®Google Scholar
• Qiao Q, Zhang J, Wang W, Li Q. Over expression of transforming growth factor and epidermal growth factor receptor in human hepatic cirrhosis tissues. Hepatogastroenterology. 2008;55(81):169–172.18507100
   PubMedGoogle Scholar
• Ma R, Xu H, Wu J, et al. Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer. Oncotarget. 2017;8(12):18901–18913. doi:10.18632/oncotarget.1478228121629
   PubMedGoogle Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127. doi:10.1056/NEJMra1001683.21992124
   PubMed Web of Science ®Google Scholar
• Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of ErbB receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84(10):1377–1383. doi:10.1054/bjoc.2000.158011355950
   PubMed Web of Science ®Google Scholar
• Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008;129(2):245–251. doi:10.1309/WF10QAAED3PP93BH18208805
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Keng VW, Sia D, Sarver AL, et al. Sex bias occurrence of hepatocellular carcinoma in poly7 molecular subclass is associated with EGFR. Hepatology. 2013;57(1):120–130. doi:10.1002/hep.2600422899566
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52‑67. doi:10.1016/j.cell.2010.03.015
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–410. doi:10.1038/nrc109312778130
   PubMed Web of Science ®Google Scholar
• Auyeung KK, Ko JK. Angiogenesis and oxidative stress in metastatic tumor progression: pathogenesis and novel therapeutic approach of colon cancer. Curr Pharm Des. 2017;23(27):3952–3961. doi:10.2174/138161282366617022812410528245762
   PubMed Web of Science ®Google Scholar
• Baitello ME, Tenani GD, Ferreira RF, et al. VEGF polymorphisms related to higher serum levels of protein identify patients with hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2016;2016:9607054. doi:10.1155/2016/960705427660750
   PubMed Web of Science ®Google Scholar
• Lorente L. New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma. World J Gastroenterol. 2018;24(37):4230–4242. doi:10.3748/wjg.v24.i37.423030310256
   PubMed Web of Science ®Google Scholar
• Elewa MA, Al-Gayyar MM, Schaalan MF, et al. Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers. Clin Exp Metastasis. 2015;32(5):479–493. doi:10.1007/s10585-015-9721-625999065
   PubMed Web of Science ®Google Scholar
• Lempinen M, Lyytinen I, Nordin A, et al. Prognostic value of serum MMP-8, −9 and TIMP-1 in patients with hepatocellular carcinoma. Ann Med. 2013;45(7):482–487. doi:10.3109/07853890.2013.82377923962148
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen X, Ding X, Wang Y. Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh‑7 cells by regulating the ERK‑VEGF/MMP-9 signaling pathway. Mol Med Rep. 2019;20(4):3317–3325. doi:10.3892/mmr.2019.1056231432165
   PubMed Web of Science ®Google Scholar
• Zhou B, Fan Y, Rao J, et al. Matrix Metalloproteinases-9 deficiency impairs liver regeneration through epidermal growth factor receptor signaling in partial hepatectomy mice. J Surg Res. 2015;197(1):201–209. doi:10.1016/j.jss.2015.03.08125956184
   PubMed Web of Science ®Google Scholar
• Hiratsuka S. Vasculogenesis, angiogenesis and special features of tumor blood vessels. Front Biosci. 2011;16:1413–1427. doi:10.2741/3796
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Nakamura K, Iwai S, et al. MMP-9 induction by vascular endothelial growth factor receptor‑1 is involved in lung‑specific metastasis. Cancer Cell. 2002;2(4):289–300. doi:10.1016/S1535-6108(02)00153-812398893
   PubMed Web of Science ®Google Scholar
• Menzo S, Clementi M, Alfani E, et al. Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus x-gene product. Virology. 1993;196(2):878–882. doi:10.1006/viro.1993.15508396816
   PubMed Web of Science ®Google Scholar
• Chen YJ, Chien PH, Chen WS, et al. Hepatitis B virus-encoded x protein downregulates EGFR expression via inducing microRNA-7 in hepatocellular carcinoma cells. Evid Based Complement Altern Med. 2013;2013:682380.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.2991329624699
   PubMed Web of Science ®Google Scholar
• Radu P, Dufour JF. Changing TACTICS in intermediate HCC: TACE plus sorafenib. Gut. 2020;pii: gutjnl–2020–320692.
   PubMed Web of Science ®Google Scholar
• Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9(2):221–232. doi:10.1016/j.jceh.2019.01.00431024205
   PubMed Web of Science ®Google Scholar
• Choi J, Lee D, Shim JH, et al. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. PLoS One. 2020;15(3):e0229696. doi:10.1371/journal.pone.022969632130270
   PubMed Web of Science ®Google Scholar
• Lanaya H, Natarajan A, Komposch K, et al. EGFR has a tumor-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol. 2014;16(10):972–977. doi:10.1038/ncb303125173978
   PubMed Web of Science ®Google Scholar
• Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol. 2010;52(2):296–304. doi:10.1016/j.jhep.2009.11.01020006399
   PubMedGoogle Scholar
• Li L, Zhao W, Wang M, et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2018;18(1):138. doi:10.1186/s12876-018-0849-030180810
   PubMedGoogle Scholar